Please use this identifier to cite or link to this item:
Title: Tau imaging with PET: an overview of challenges, current progress, and future applications
Austin Authors: Robertson, Joanne S;Rowe, Christopher C ;Villemagne, Victor L 
Affiliation: The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Victoria, Australia
Department of Molecular Imaging and Therapy and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
Issue Date: Dec-2017 2017-07-27
Publication information: Quarterly Journal of Nuclear Medicine and Molecular Imaging 2017; 61(4): 405-413
Abstract: Folded and misfolded tau is common to many neurodegenerative conditions, collectively termed 'tauopathies'. In recent years, many efforts have contributed toward development of tau imaging agents to allow measurement of tau deposits in vivo using Positron Emission Tomography (PET). The particularities of tau present some unique challenges for the development of tau imaging tracers. Most notably, these pertain to the predominantly intracellular nature of tau aggregations, the existence of six isoforms, multiple post-translational modification, and that tau is usually surrounded by larger concentrations of A plaques. Nevertheless, significant progress has been made towards overcoming these issues and a number of tracers are now undergoing human trials. Once validated, tau imaging with PET will be a useful tool for the differential diagnosis and disease staging, as well as therapeutic trials of AD and non-AD tauopathies.
DOI: 10.23736/S1824-4785.17.03012-6
ORCID: 0000-0003-3910-2453
Journal: Quarterly Journal of Nuclear Medicine and Molecular Imaging
PubMed URL: 28750496
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Jan 30, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.